Financial Data and Key Metrics Changes - In 2025, the company generated $255 million in total revenues, representing a 29% growth compared to 2024 [11] - Total assets under management (AUM) reached $50 billion at year-end, up 10% year-over-year [13] - Adjusted EBITDA increased 45% to approximately $35 million for the year [17] - The company reported a net loss of $155 million for the year, largely driven by non-cash non-recurring items [18] Business Line Data and Key Metrics Changes - The core revenue base remained anchored in nearly $200 million of predictable recurring management fees, which increased by 9% year-over-year [11][15] - The endowment and foundation business grew to more than $8 billion in AUM at year-end 2025 [8] - Incentive fees contributed significantly to revenue, with a $29 million contribution in the fourth quarter alone [14] Market Data and Key Metrics Changes - The company experienced strong demand from ultra-high net worth and institutional clients across U.S. and international businesses, adding nearly $4 billion in projected billable assets in 2025 [9] - The international business faced foreign exchange headwinds due to U.S. dollar depreciation, impacting growth [13] Company Strategy and Development Direction - The company aims to build a premier global wealth management platform focused on the ultra-high net worth segment [4] - A strategic assessment led to the exit of the non-core International Real Estate business, allowing for a simplified organizational structure [10] - The adoption of zero-based budgeting is expected to yield approximately $20 million in recurring annual gross savings by year-end 2026 [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver sustained growth and increased profitability over time, supported by a focused strategy and durable client relationships [19] - The company anticipates that 2026 will mark a turning point, with improved visibility of operating leverage and expense trends as initiatives take hold [18] Other Important Information - The company has formed a special committee to review strategic options to maximize long-term shareholder value, with no proposals received to date that encapsulate the business's long-term value [12] Q&A Session Summary Question: Could you provide more color on the decision to transition CEOs? - Management indicated that the transition was a thoughtful decision aimed at positioning the company for its next phase of growth while maintaining continuity in strategy [24] Question: Can you provide an update on the zero-based budgeting (ZBB)? - ZBB is expected to yield $20 million in savings over approximately nine quarters, with improvements in non-comp expenses and occupancy costs anticipated as contracts expire [47] Question: What is the status of Allianz's 13D filing? - Allianz has been a strategic partner, and any plans to increase engagement would require a filing, but there is currently no visibility into their intentions [43][44] Question: Can you discuss the merger arbitrage performance? - The merger arbitrage strategy performed well in 2025, generating an 11.3% return, which positively impacted management fees and incentive fees [35][36] Question: What is the outlook for capital and potential acquisitions? - The company does not foresee a need for funding for organic growth initiatives but is confident in its ability to raise capital for attractive inorganic opportunities if identified [51][53]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 increased approximately 9% year-over-year to $140.7 million, driven primarily by wholesale growth [5][20] - Adjusted EBITDA for Q4 was approximately $8.8 million, a significant improvement from $2.9 million in the previous year [5][23] - Full-year 2025 net revenue was $468.7 million, reflecting a 3.9% decline compared to the prior year [20][24] - Full-year adjusted EBITDA was $1.9 million, a notable improvement from an adjusted EBITDA loss of $20.8 million in 2024 [26] Business Line Data and Key Metrics Changes - Direct-to-consumer (DTC) net revenue for Q4 was $71.9 million, down 9.9% year-over-year, with showroom revenue increasing approximately 4.5% [21] - Wholesale revenue surged approximately 39.8% in Q4, driven by expanded partnerships with Mattress Firm and Costco [8][21] - E-commerce revenue declined by 15.3% in Q4, although there were strong sales during Black Friday and Cyber Monday [8][21] Market Data and Key Metrics Changes - Comparable sales in showrooms increased 8.8% in Q4, with over 80% of showrooms being four-wall profitable for the full year [7][21] - The overall market for the company is down low single digits, yet the company has shown growth in its sales channels [7][8] Company Strategy and Development Direction - The company is focused on three priorities: understanding consumers better, enhancing product experience, and executing with financial discipline [8][9] - The launch of the Purple Royale collection is a significant step in the company's premium strategy, complementing the Rejuvenate 2.0 collection [11][12] - The company aims to expand its distribution presence, particularly through partnerships with Mattress Firm and Costco, which have exceeded initial expectations [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's improved stability and operational model as it enters 2026, expecting revenue between $500 million and $520 million [17][18] - The company anticipates adjusted EBITDA of $20 million to $30 million for 2026, driven by continued momentum in its premium product portfolio [18][28] - Management acknowledged ongoing strategic alternatives to maximize shareholder value, including potential mergers or sales [18] Other Important Information - The company ended Q4 with cash and cash equivalents of $24.3 million, down from $29 million a year prior, but still positioned well from a liquidity standpoint [26][27] - The company has extended its debt maturities to April 2027, enhancing financial flexibility [27][30] Q&A Session Summary Question: Recent trends and outlook for Q1 - Management noted that Q1 is typically the weakest quarter, but they expect momentum to build throughout the year despite a slower start in January due to inventory dynamics [34][35] Question: Flow-through margin expectations - Management indicated that flow-through should be strong, with a typical 30% flow-through expected, enhanced by margin expansion and cost control [38] Question: Exposure to raw material price pressures - Management acknowledged mixed exposure to petrochemical prices but indicated that tariff savings could offset potential increases in raw material costs [40][41] Question: Seasonality and revenue growth expectations - Management expects consistent revenue growth throughout the year, with a natural build into Q3 and Q4, aided by new product launches [51] Question: Cash flow expectations for 2026 - Management anticipates positive free cash flow for 2026, supported by improved EBITDA profitability [68] Question: Demand trends in retail partners - Management reported mixed performance across wholesale partners, with some showing growth while others lagged behind [67] Question: Rollout of new products - The rollout of new products is complete, with ongoing opportunities for growth in various channels [78]

Financial Data and Key Metrics Changes - For Q4 2025, revenue was $12.5 million, roughly even compared to the previous year, with gross profit increasing to $3.4 million from $2.8 million in Q4 2024, resulting in a gross margin of 27% compared to 22% in the same period last year [4][5] - Full year 2025 revenue reached a record $62.1 million, up 18.6% from $51.9 million in 2024, while full year gross profit was $16.1 million, slightly down from $16.2 million in 2024 [5][6] - Adjusted EBITDA for 2025 was $4.2 million, less than 7% of revenue, with a target to improve EBITDA to double digits in 2026 [6][7] Business Line Data and Key Metrics Changes - The company launched 20 new brand partners in 2025, contributing to substantial revenue growth [5] - The operational challenges faced in 2025 included elevated labor costs, product design issues, and inventory control problems, which compressed margins [6][10] Market Data and Key Metrics Changes - The company anticipates a normalization of revenue in 2026, with a current shift in open orders at just under $33 million compared to $38 million a year ago [8][17] - The beauty sector remains resilient, with consumers viewing beauty as an affordable luxury, particularly in SPF-infused skincare [16] Company Strategy and Development Direction - The company initiated the "Transform and Transcend" strategy to enhance operational health and achieve a gross margin floor of 30% in 2026 [7][11] - The strategy focuses on operational excellence, technology-driven expansion, a new product development model, and collaborative globalization [12][14] - The company aims to leverage its patent portfolio to expand into adjacent prestige beauty segments and improve profitability [9][14] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that 2026 will be a year focused on execution, addressing operational challenges to ensure sustainable profitability [17][41] - The company is optimistic about the future, expecting to stabilize its foundation in 2026 and set the stage for significant profitability in the following years [41] Other Important Information - The company has increased its patent portfolio by 20%, now totaling over 120 patents, which strengthens its market position [9] - The new product, Day Mode Hero Concealer, has been recognized in multiple categories, indicating strong market potential [10] Q&A Session Summary Question: Will EPS in 2026 be at or above the 2024 levels? - Management is not prepared to provide EPS guidance for 2026 but expects an increase in EBITDA to return to double digits [19][20] Question: What is the roadmap for growth to $200 million? - The company is addressing operational execution challenges and targeting growth in the fastest-growing market segments, with aspirations for higher profit margins [24][26] Question: Why has production struggled? - The company faced challenges due to simultaneous growth and the installation of new capabilities, but is confident in future performance improvements [34][35] Question: Did the company lose a brand partner? - Management clarified that there was no loss of any brand partner, but noted challenges with sell-through from one of their large mass-market customers [35][36] Question: Why did it take so long to schedule the call? - The call was scheduled after the year-end audit was completed, which is planned almost a year in advance [36]

Financial Data and Key Metrics Changes - The company ended 2025 with a cash balance of $13.4 million, an increase from $4.6 million in 2024, while operating costs decreased nearly 40% over the year [14][19] - The net loss for Q4 2025 was $2.6 million or $0.56 per share, compared to $2.5 million or $0.62 per share for Q4 2024. For the full year, the net loss was $12.5 million or $2.93 per share, compared to $10.8 million or $2.86 per share in 2024 [19] Business Line Data and Key Metrics Changes - MiNK cells are in phase II clinical trials for solid tumor cancers and autoimmune inflammatory conditions, demonstrating durable survival beyond 23 months and complete remission extending beyond two years in heavily pretreated refractory cancers [3][6] - The company is advancing trials in graft versus host disease (GVHD) and severe hypoxemic pneumonia, with significant external funding secured for these initiatives [4][11] Market Data and Key Metrics Changes - The hypoxemic pneumonia market affects approximately 200-300,000 patients annually, with a mortality rate of 30%-40% and no approved disease-modifying therapies [8][10] - The company is targeting a specific patient population for its ARDS trial, utilizing a global ARDS definition to ensure precise selection based on oxygenation and organ function [35] Company Strategy and Development Direction - The company is focused on capital efficiency, combining disciplined internal execution with non-dilutive funding through government and institutional partnerships [5][12] - The strategic approach includes advancing a PRAME-targeted TCR-engineered iNKT program, leveraging collaborations to enhance platform capabilities without significant capital burden [13][14] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of demonstrating durability and mechanistic validation of their technology in 2025, setting the stage for future clinical advancements [21] - The company expects to initiate a randomized phase II/III ARDS study and dosing in the GVHD trial in the first half of 2026, with initial clinical data anticipated in the second half of the year [17][21] Other Important Information - The company has appointed Melissa Orilall as Principal Financial Officer to strengthen financial leadership and ensure alignment in capital allocation and operational execution [15] - The company has secured multiple sources of non-dilutive capital funding, including NIH funding and philanthropic support, to advance clinical programs and expand the pipeline [12][14] Q&A Session Summary Question: Can you discuss the phase II pneumonia and ARDS study, including patient numbers and control arm? - Management indicated that the trial will involve patients treated with standard care, with the MiNK cells added on top, emphasizing the unique ability of the cells to modulate immune function even in the presence of steroids [25][26] Question: What is the status of the second-line gastric cancer trial and when will efficacy data be available? - Efficacy data from the gastric cancer trial is expected to be presented at a major conference in the first half of the year [29] Question: What differentiating aspects does the company consider for IPF and GVHD patient populations? - Management highlighted the immune-related nature of IPF and the potential for MiNK cells to provide benefits, with plans for a responsible funding approach for the trial [30][33] Question: Can you clarify the combination approach with the IL-15 iNKT cell trial? - Management clarified that no formal announcement has been made regarding collaborations with IL-15 superagonists, and any strategic collaborations will be publicly disclosed at the appropriate time [44][45]

Financial Data and Key Metrics Changes - For the fourth quarter, AirJoule Technologies reported net operating expenses of $3.2 million, with full-year net operating expenses at $13.6 million, up from $11.2 million in 2024, primarily due to a $4.2 million increase in non-cash stock-based compensation [28][29] - The net loss for the full year is $9 million, with a loss from investment in AirJoule JV of $39.3 million, compared to $5.3 million for the full year 2024 [29][30] - AirJoule Technologies ended 2025 with approximately $22 million in cash, and after a January 2026 equity offering, the combined cash position across AirJoule Technologies and the JV was approximately $44 million with no debt [31][32] Business Line Data and Key Metrics Changes - The company focused on technology validation, product development, and partnerships, achieving significant milestones in deploying AirJoule systems in various locations, including Texas, Arizona, California, and Dubai [8][9] - The AirJoule Core product, optimized for industrial dehumidification and water generation, is expected to be commercially available in late Q4 2026, while the larger AirJoule Prime system is currently under construction [19][20] Market Data and Key Metrics Changes - The Middle East is highlighted as a critical market due to its water stress, with Gulf nations relying on desalination for 70%-90% of their drinking water, creating a significant opportunity for AirJoule's distributed water generation technology [15][16] - The ongoing geopolitical conflicts have increased the urgency for water resilience, reinforcing the demand for AirJoule's solutions in the region [17] Company Strategy and Development Direction - The company aims to transition to a commercial pipeline in 2026, focusing on securing long-term customer commitments across various sectors, including data centers, industrial, defense, and international markets [13][14] - AirJoule's strategy includes leveraging partnerships, such as with GE Vernova and TenX, to accelerate commercialization and expand market access [11][12] Management's Comments on Operating Environment and Future Outlook - Management emphasized the growing urgency of water resilience due to environmental and geopolitical factors, positioning AirJoule's technology as a solution to these challenges [4][5] - The company expects 2026 to be a pivotal year for building customer relationships and deploying systems that will lay the groundwork for scaled commercial activity in 2027 and beyond [27][71] Other Important Information - The company has established a water purchase agreement business model, which has been well received by customers, and is expected to support long-term gross margins of 30%-35% at scale [50][56] - The company is actively engaged in customer outreach through direct engagement, warm introductions, and participation in conferences and trade shows [38][39] Q&A Session Summary Question: Customer engagement strategies - The company engages customers through direct outreach, warm introductions, and participation in industry events, with a focus on addressing urgent water needs in sectors like data centers [36][39] Question: Supply chain concerns - Most components are commercially available, with the only custom part being the sorbent chamber, which is produced at scale [40][41] Question: Capital expenditure needs for 2026 - The anticipated capital calls for the joint venture are part of the normal funding plan, with no major additional CapEx expected for 2026 [43][45] Question: Expected gross margins - Initial gross margins are less emphasized, with long-term targets of 30%-35% as the company transitions to contract manufacturing [50][51] Question: Competing with desalination - AirJoule's technology offers advantages in speed to market and water quality, despite desalination being cheaper in operating costs [53][54]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $32.4 million, a 3% increase from $31.5 million in Q4 2024, despite a $2 million revenue loss due to the early closure of the Companion Spine transaction [4][14] - Full year 2025 revenue reached $133.9 million, representing a 14% growth from $117.3 million in 2024 [7][16] - Adjusted EBITDA for Q4 2025 was $1.9 million, compared to approximately $0.4 million in Q4 2024, while full year adjusted EBITDA was $16.3 million, a significant improvement from a loss of $2.3 million in 2024 [19][16] - Net income for Q4 2025 was $57,000, or $0.00 per share, compared to a net loss of $3.2 million, or $0.02 per share in Q4 2024 [16] Business Line Data and Key Metrics Changes - The biologics product family was essentially flat in Q4 2025, with a focus on high-margin products expected to drive future growth [7][8] - Sales and marketing expenses for Q4 2025 were $10.9 million, down from $11.7 million in Q4 2024, primarily due to reduced commission expenses [15] - Research and development expenses decreased to $459,000 in Q4 2025 from $522,000 in Q4 2024 [15] Market Data and Key Metrics Changes - The company anticipates continued organic growth in its core biologics business, with expectations for revenue in 2026 to be between $95 million and $99 million [12] - The loss of license revenue from Q-Code and amniotic membrane agreements is expected to impact 2026 revenue, but the company is optimistic about ramping up its advanced wound care products [28][29] Company Strategy and Development Direction - The company has sharpened its focus on its core high-margin biologics business following the sale of non-core assets, which is seen as a transformational move [5][6] - Plans to double the number of regional sales representatives and expand the national accounts team are in place to drive institutional adoption and revenue growth [9][12] - The company is committed to maintaining positive free cash flow and does not anticipate the need for additional outside capital [5][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's operational discipline and the successful execution of strategic initiatives aimed at self-sustainability and cash flow generation [8][12] - The outlook for 2026 includes expectations for sequential quarter-over-quarter growth, driven by new product offerings and an expanded commercial organization [26] Other Important Information - The gross margin for Q4 2025 was 54.9%, an increase from 50.8% in Q4 2024, attributed to a favorable sales mix [14] - The company had $17.3 million in cash equivalents and restricted cash as of December 31, 2025, compared to $6.2 million a year earlier [20] Q&A Session Summary Question: Outlook for 2026 and organic growth in core biologics business - Management expects sequential quarter-over-quarter growth in 2026, with biologics in Q1 anticipated to be down low double digits compared to Q1 2025 due to headwinds from lost amnio product [26][27] Question: Impact of loss of license revenue from Q-Codes - The Q-Code revenue will completely go away, but management anticipates ramping up sales of their own branded products in advanced wound care as the year progresses [28][29] Question: Decline in hardware business throughout 2026 - A slow decline in the hardware business is expected throughout the year, with a projected decline approaching high teens percentage [31] Question: Growth drivers in biologics and distribution channels - Key growth drivers include advanced biologics products like OsteoVive Plus and CollagenX, with approximately 20-22% of growth expected from OEM channels [36][40] Question: Strategic thoughts on hardware business and gross margin in 2026 - Management is evaluating the hardware business as a potential strategic distraction but sees current offerings as strong. Gross margin for 2026 is expected to be in the low 60s percentage [46][48]

Financial Data and Key Metrics Changes - For the full year 2025, revenues reached $427 million, representing a 142% year-over-year increase from the prior year [13] - Gross profit increased by 340% to $96.3 million in 2025, up from $21.9 million in 2024, with gross profit margin expanding to 22.5% from 12.4% in 2024 [13][14] - EBITDA was $95.8 million in 2025, a 40% increase from $68.2 million in the prior year, while non-GAAP adjusted EBITDA was $110.8 million, up by 228% compared to $33.8 million for the same period in the prior year [15] - GAAP net income was $37.2 million for 2025, compared to $40.5 million for the same period last year, while adjusted net income was $52.2 million, compared to $6 million in 2024 [15][16] Business Line Data and Key Metrics Changes - The primary growth driver was a $241 million increase in solar cell sales, with an additional $7.6 million increase in module sales [13] - The company successfully shipped 2.3 gigawatts from Ethiopia to U.S. end customers and 1.9 gigawatts from Vietnam to international markets [6] Market Data and Key Metrics Changes - The company is positioned to meet the accelerating demand in the U.S. solar market, with shipment guidance for 2026 set between 5.5 and 5.8 gigawatts for solar cells and 1 to 1.3 gigawatts for solar modules [10][11] - The operational focus for 2026 includes maximizing existing infrastructure, particularly the Ethiopia cell facility and the Houston module facility [11] Company Strategy and Development Direction - The company aims to scale production continuously in 2026 and invest to expand capacity in Houston to 2 gigawatts [8] - The acquisition of the BridgeSun brand is intended to streamline operations and enhance growth without diluting shareholder value [9] - The company is committed to strengthening its supply chain by migrating sourcing of key components to the U.S. [9] Management's Comments on Operating Environment and Future Outlook - Management highlighted the successful navigation of a volatile trade environment and the establishment of a resilient foundation for future growth [5] - The company anticipates adjusted net income of approximately $90 million to $100 million for 2026, despite significant investments in R&D and technology [12] Other Important Information - The company generated cash flow from operations of $133 million in 2025, with $92 million of CapEx invested in manufacturing facilities [17] - The management team has been strengthened with the appointment of Rhone Resch as Chief Strategy Officer [2] Q&A Session Summary Question: Insights on gross margins with increased U.S. revenue share - Management indicated that they expect to maintain competitive margins as the Ethiopia facility operates at full capacity and the U.S. factory comes online [20][22] Question: Potential credits for Houston production capacity in 2026 - Management is cautious about providing guidance for Houston production but anticipates achieving 60%-70% utilization of the current 1 gigawatt capacity [25][26] Question: Future frequency of earnings calls - The company plans to report quarterly starting this year, with the first quarter numbers expected in May [27]

Financial Data and Key Metrics Changes - The company ended 2025 with a cash balance of $13.4 million, an increase from $4.6 million in the previous year, while operating costs decreased nearly 40% [14][20] - The net loss for Q4 2025 was $2.6 million or $0.56 per share, compared to $2.5 million or $0.62 per share for Q4 2024. For the full year, the net loss was $12.5 million or $2.93 per share, compared to $10.8 million or $2.86 per share in 2024 [20] Business Line Data and Key Metrics Changes - MiNK cells are currently in phase II clinical trials for solid tumor cancers and autoimmune inflammatory conditions, demonstrating durable survival beyond 23 months in heavily pretreated refractory cancers [3][6] - The company is advancing a trial in graft versus host disease (GVHD) and a phase II trial in gastric cancer, with results expected to be presented at a major conference in the first half of 2026 [4][11] Market Data and Key Metrics Changes - The company is targeting a significant patient population for hypoxemic pneumonia or ARDS, affecting approximately 200,000-300,000 patients annually, with a mortality rate of 30%-40% [8][10] - The company has observed substantial clinical activity in patients with severe acute respiratory distress, showing prolonged survival rates compared to hospital controls [9] Company Strategy and Development Direction - The company is focused on capital efficiency, combining disciplined internal execution with non-dilutive funding through government and institutional partnerships [5][12] - The strategic collaboration with the C-Further Consortium aims to advance the PRAME-targeted TCR-engineered iNKT program, reflecting external validation of the platform's maturity [13][14] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of generating clear, interpretable data to inform future development and regulatory pathways, with multiple readouts planned for the first half of 2026 [17][22] - The company is excited about the upcoming randomized controlled clinical trials and anticipates initial clinical data in the second half of 2026 [22] Other Important Information - The company has appointed Melissa Orilall as Principal Financial Officer to strengthen financial leadership and ensure alignment in capital allocation and operational execution [15] - The company has secured multiple sources of non-dilutive capital funding, including NIH funding and philanthropic support, to advance clinical programs without diluting shareholder equity [12][14] Q&A Session Summary Question: Can you discuss the phase II pneumonia and ARDS study and the control arm? - Management indicated that the trial will involve patients treated with standard of care, primarily steroid therapy, and that the cells will be added on top of this standard [25][26] Question: What is the status of the second-line gastric cancer trial? - Efficacy data from the gastric cancer trial is expected to be presented in the first half of 2026 at a major conference [31] Question: What differentiating aspects does the company consider for IPF and GVHD? - Management noted that the patient populations for ARDS will be specifically identified based on oxygenation and organ function, with no approved therapies currently available [35][38] Question: Can you clarify the combination approach with the IL-15 iNKT cell trial? - Management clarified that the company has not formally announced any collaboration regarding the IL-15 superagonist and will be public about any strategic collaborations in the future [46][48]

Financial Data and Key Metrics Changes - In 2025, B.O.S. achieved record revenues of $51 million, representing a 27% year-over-year growth, while net income increased by 57% to a record $3.6 million [2][4] - The company ended 2025 with a contracted backlog of $24 million, providing good visibility for the upcoming year [2] Business Line Data and Key Metrics Changes - The defense sector continues to drive growth in the supply chain and Robotics Division, with strong backlog visibility and customer relationships [3] - The RFID Division faced challenges due to geopolitical tensions in Israel, leading to goodwill impairment charges of $1.2 million in 2025 [4][7] Market Data and Key Metrics Changes - The USD to Israeli shekel exchange rate saw a 13% devaluation of the dollar against the shekel at the start of 2026, impacting operating expenses by an estimated $600,000 [6][7] - The company recognized $800,000 in non-recurring currency exchange income in 2025, which is not expected to repeat in 2026 [6][7] Company Strategy and Development Direction - B.O.S. is focusing on expanding its geographic reach, particularly in India, which is becoming a subcontracting hub for global defense programs [3] - The strategic plan for 2026 includes entering the hospital segment to reduce exposure to the Israeli civilian market, with expected revenue contributions starting in 2027 [4][5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the defense segment's growth despite ongoing geopolitical tensions, indicating that the war could positively affect the growth of the defense and Robotics divisions [13][14] - The company maintains a conservative outlook for 2026, projecting revenues and net income to remain at approximately $51 million and $3.6 million, respectively, while acknowledging the potential for upward revisions [9][16] Other Important Information - B.O.S. has a strong balance sheet with cash and equivalents growing to $11.8 million, and shareholders' equity increasing to nearly $29 million [7][9] - The company plans to shift its investor relations strategy towards digital marketing to enhance market awareness and visibility [10][11] Q&A Session Questions and Answers Question: Impact of ongoing war on business - Management indicated that the defense segment would likely benefit from prolonged conflict, while the RFID Division remains sensitive to geopolitical tensions [13][14] Question: Guidance for revenue growth - Management clarified that the guidance reflects a conservative approach, with a strong backlog supporting future growth potential [15][16] Question: M&A strategy and cash utilization - The company is evaluating several acquisition opportunities and plans to invest cash in securities until suitable M&A opportunities arise, with no expected dilution from acquisitions [17][20] Question: Revenue from India - Management confirmed that revenue from India averaged around $3 million over the past three years, with expectations for significant growth moving forward [22][54] Question: RFID investment in the hospital market - Initial investment in the hospital segment is expected to be around $200,000 in 2026, with profitability anticipated by 2028 [26][28] Question: Tax implications for 2026 - Management expects to utilize tax loss carryforwards, resulting in no significant tax expenses for 2026 [40][41]

Financial Data and Key Metrics Changes - The company ended 2025 with a cash balance of approximately $13.4 million, an increase from $4.6 million in the previous year [14] - The net loss for Q4 2025 was $2.6 million or $0.56 per share, compared to a net loss of $2.5 million or $0.62 per share in Q4 2024 [19] - For the full year, the net loss was $12.5 million or $2.93 per share, compared to $10.8 million or $2.86 per share in 2024, reflecting continued investment in clinical programs while controlling operational spending [19] Business Line Data and Key Metrics Changes - The company is advancing its MiNK iNKT cell platform, which is currently in phase II clinical trials for solid tumor cancers and autoimmune inflammatory conditions [3][4] - Clinical activity has been observed in patients with hypoxemic pneumonia, with a planned randomized phase II trial to begin soon [4][10] - The company has secured external funding for trials in graft versus host disease (GVHD) and gastric cancer, with results expected to be presented at major conferences [4][11] Market Data and Key Metrics Changes - The company is targeting a significant patient population for its hypoxemic pneumonia treatment, which affects approximately 200,000 to 300,000 patients annually with a mortality rate of 30%-40% [8][10] - The company is also focusing on the pediatric oncology market through its collaboration with the C-Further Consortium, which reflects external validation of its platform [13] Company Strategy and Development Direction - The company aims to restore immune function in various diseases, leveraging a capital-efficient model that combines internal execution with non-dilutive funding [5][12] - The strategy includes advancing clinical programs in immune-mediated diseases without incremental capital burden, supported by non-dilutive funding sources [12][14] - The company plans to initiate a randomized phase II/III study for ARDS and activate its GVHD trial in 2026, with initial clinical data expected in the second half of the year [17] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of demonstrating durability and mechanistic validation of their technology in 2025, setting the stage for future clinical advancements [21] - The company is focused on generating clear, interpretable data to inform development and regulatory pathways, with multiple readouts planned for 2026 [17] Other Important Information - The company appointed Melissa Orilall as Principal Financial Officer to strengthen financial leadership and ensure alignment in capital allocation and operational execution [15] - The company has seen increased external interest in its iNKT biology and is exploring strategic partnerships, although no formal collaborations have been announced yet [16][45] Q&A Session Summary Question: Can you discuss the phase II pneumonia and ARDS study, including patient numbers and control arms? - The company has not publicly posted the program details but will use physician's choice as the control arm, with the cells added on top of standard care [25][26] Question: What is the status of the second-line gastric cancer trial and when will efficacy data be available? - Efficacy data from the gastric cancer trial will be presented in the first half of the year at a major conference [30] Question: What differentiating aspects does the company consider for IPF and GVHD patient populations? - The company is focusing on immune-related conditions and has preclinical observations supporting the development of cells in IPF [34][36] Question: Can you clarify the IL-15 iNKT cell combination trial and its relation to the randomized controlled trial in ARDS? - The company has not formally announced any collaboration regarding the IL-15 superagonist and will provide updates when appropriate [44][45]